Phase III trial data demonstrates positive results of sugemalimab in stage III NSCLC

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment, according to a Mayo Clinic-led study.

February 27, 2026

Vol.52 No.08

Drugs & Targets

FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC

FDA approved Hernexeos (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.

February 27, 2026

Vol.52 No.08

In Brief

WVU Cancer Institute first in the world to treat ultra-rare leukemia using novel subcutaneous immunotherapy

A WVU Cancer Institute team has achieved a global medical first in a clinical trial examining the efficacy of subcutaneous blinatumomab (Blincyto) in treating one of the rarest and most aggressive forms of leukemia.

February 20, 2026

Vol.52 No.07

Clinical Roundup

Neoadjuvant pembrolizumab helps shrink tumors in patients with desmoplastic melanoma

In a recent multi-institutional clinical trial, 71% of patients who received the immunotherapy drug pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, before surgery had no detectable cancer remaining at the time of surgery.

February 06, 2026

Vol.52 No.05

Clinical Roundup

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

Researchers at The University of Texas MD Anderson Cancer Center have determined that mutations in the KDM6A gene—common in advanced bladder cancer—may serve as a predictive biomarker to determine which patients are less likely to benefit from standard chemotherapy but may respond better to immunotherapy.

January 16, 2026

Vol.52 No.02

Phase III trial data demonstrates positive results of sugemalimab in stage III NSCLC

YOU MAY BE INTERESTED IN

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC

WVU Cancer Institute first in the world to treat ultra-rare leukemia using novel subcutaneous immunotherapy

Neoadjuvant pembrolizumab helps shrink tumors in patients with desmoplastic melanoma

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

Renew today!

Subscriber content

Never miss an issue!

Login